Medical Bulletin 22/June/2026

Here are the top medical news for today:

WHO Releases First-Ever Guidelines for Paediatric Dengue Treatment and Clinical Care

As dengue cases continue to rise worldwide, the World Health Organization (WHO) has released its first-ever guidance focused on developing dengue treatments specifically for children. The new recommendations aim to accelerate research into safe, effective, and child-friendly medicines for one of the world's fastest-growing mosquito-borne diseases.

According to WHO, more than 14 million dengue cases and over 10,000 related deaths were reported globally in 2024. Children, particularly younger ones, are at greater risk of developing severe dengue and life-threatening complications. Despite the growing burden, there are currently no approved antiviral medicines specifically designed to treat dengue.

The new guidance is based on WHO's first Paediatric Drug Optimization Process (PADO) for dengue, which identifies the most promising treatment candidates for children and outlines research priorities to speed up the development of pediatric therapies.

A major focus of the guidance is ensuring that children are included from the earliest stages of drug development rather than adapting adult medicines later. WHO says children require different doses, formulations, and treatment approaches, making pediatric-specific research essential. The organization is also encouraging the development of child-friendly medicines, such as liquid formulations and dispersible tablets that are easier for young children to take.

The report further calls for greater investment and collaboration among governments, researchers, pharmaceutical companies, funding agencies, and regulatory authorities to advance dengue therapeutics. Researchers are being urged to prioritize antiviral drugs that could reduce disease severity and prevent serious complications.

WHO emphasizes that early diagnosis and supportive medical care remain the only available treatment for dengue until effective antiviral therapies become available. By providing a clear roadmap for pediatric drug development, the agency hopes to accelerate the arrival of safe and effective dengue treatments that can better protect children living in dengue-endemic regions.

REFERENCE: WHO issues first ever guidance to advance child-focused dengue treatments; Paediatric drug optimization for dengue: meeting report, 23 October 2025; https://www.who.int/publications/i/item/9789240121409

New Study Links Childhood Trauma to Faster Cellular Ageing and Health Risks

Experiencing adversity during childhood may leave a lasting biological imprint that changes how the body's cells produce energy well into adulthood, according to a new study published in Biological Psychiatry. Researchers found that while these cellular changes may initially help the body cope with stress, they could become harmful over time and contribute to poorer physical and mental health.

The study included more than 140 adult men and women who completed questionnaires about adverse childhood experiences and provided blood samples for laboratory testing. Researchers then performed a "stress test" on living cells to examine how their mitochondria—the tiny structures responsible for producing energy inside cells—responded under stress.

The findings showed that adults who experienced greater early-life adversity had mitochondria with a higher respiratory capacity, meaning their cells could generate more energy when exposed to stress. Researchers believe this "hypermetabolic" state may help cells respond rapidly to challenging situations. However, if mitochondria remain in this heightened state for years, they may become overworked, potentially accelerating cellular damage and increasing the risk of age-related diseases.

The researchers also found that different types of childhood adversity affected mitochondrial function in distinct ways. Experiences involving threat, such as abuse or violence, were associated with lower routine energy production while maintaining the ability to respond to future stress. In contrast, experiences involving deprivation, such as neglect or lack of basic resources, were linked to less efficient energy production, suggesting greater cellular dysfunction.

The study also found that people with greater cumulative childhood adversity had lower ATP production through glycolysis—a process cells use to generate energy—and greater maximal respiratory capacity, indicating that mitochondria may shift how they produce energy after prolonged stress.

Although the findings do not prove that childhood adversity directly causes long-term health problems, they provide new insight into how early-life experiences may become biologically embedded.

REFERENCE: Cleveland S, Carroll J, Montoya A, et al; Early-Life Adversity and Mitochondrial Function: Comparing Cumulative Risk and Dimensional Models of Adversity; Biological Psychiatry, 2026; DOI: 10.1016/j.biopsych.2026.04.006

Researchers Discover Giant Tropical Fruit That Could Reverse Damage Caused by Gum Disease

A new biomaterial made from jackfruit latex, pomegranate peel extract, and the cholesterol-lowering drug simvastatin could offer a promising new approach to treating periodontitis, a severe form of gum disease that damages the tissues and bone supporting the teeth.

Developed by researchers at the Pontifical Catholic University of São Paulo (PUC-SP) in Brazil, the experimental gel is designed to tackle several aspects of gum disease at once. The findings, published in Polymer Bulletin, suggest the material could help control infection and inflammation while also promoting the regeneration of damaged periodontal tissue.

Periodontitis is a chronic inflammatory disease caused by bacterial infection. Current treatments mainly focus on removing infection and reducing inflammation but often do not restore the bone and connective tissues lost during the disease. Existing regenerative techniques, such as bone grafts, can also produce inconsistent results.

To overcome these limitations, the researchers created a mucoadhesive gel using jackfruit latex, which naturally sticks to tissues and may allow medicines to remain longer at the affected site. They combined it with pomegranate peel extract, known for its antimicrobial properties, and simvastatin, a drug that not only reduces inflammation but has also been shown to stimulate bone formation.

The team tested the biomaterial in the laboratory using human fat-derived stem cells. Simvastatin was incorporated into the gel at three different concentrations—0.3%, 0.6%, and 1.2%—all of which maintained the gel's structure and were considered technically safe.

All three formulations successfully promoted osteoinduction, the process that encourages stem cells to develop into bone-forming cells, within 14 days. The bone-forming effect became even stronger after 21 days, suggesting the material could help regenerate tissues damaged by periodontitis.

While the early laboratory findings are encouraging, the researchers emphasize that further studies are needed to confirm the biomaterial's safety and effectiveness before it can be tested in patients.

REFERENCE: Bruna V. Quevedo, Barbara B. T. de Lima, Kaique G. Hergesel, Jessica Asami, Daniel Komatsu, Eliana Aparecida de Rezende Duek. Jackfruit latex-pomegranate extract biomaterial incorporated with simvastatin as a potential osteoinductive system for periodontal applications. Polymer Bulletin, 2026; 83 (6) DOI: 10.1007/s00289-026-06358-w